Spyre Therapeutics Appoints New CCO and Outlines 2026 Priorities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy SYRE?
Spyre Therapeutics highlighted its 2026 priorities including six expected POC readouts. The Company also expanded its leadership team with the appointment of Kate Tansey Chevlen as Chief Commercial Officer, CCO. Tansey Chevlen is a biopharma commercial leader with nearly two decades of experience, joining from Ampgen where she most recently held the position of VP, Global Marketing Head for Immunology and Inflammation. Key highlights: SKYLINE platform trial in ulcerative colitis recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in Q2; SKYWAY basket trial enrollment on track across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis; All readouts expected in 4Q 2026; Strong balance sheet with pro forma cash, cash equivalents, and marketable securities balance of $783M as of September 30, 2025, anticipated to provide cash runway into the second half of 2028
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYRE
Wall Street analysts forecast SYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYRE is 56.67 USD with a low forecast of 40.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.070
Low
40.00
Averages
56.67
High
70.00
Current: 32.070
Low
40.00
Averages
56.67
High
70.00
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Spyre Therapeutics CEO Sells 15,000 Shares for $460K
- Insider Transaction: Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares on January 2 through open-market transactions for over $460,000, indicating management's approach to liquidity management in the company's stock.
- Holding Status: Post-transaction, Turtle retains approximately 671,907 shares valued at around $20.5 million, suggesting a strong confidence in the company's future prospects despite the sale.
- Transaction Context: The sale accounted for 2.2% of his direct holdings, with all shares sold being directly owned, reflecting transparency and compliance in insider trading practices.
- Market Performance: Over the past year, Spyre Therapeutics' stock has risen by 36.3%, outperforming the Nasdaq Composite's 24.3% return, indicating market recognition of its growth potential.
See More
Spyre Therapeutics CEO Cameron Turtle Sells 15,000 Shares for Over $460,000
- Insider Sale: Cameron Turtle, CEO of Spyre Therapeutics, sold 15,000 shares on January 2, 2026, for over $460,000, representing 2.2% of his holdings and reducing his direct ownership to 671,907 shares, which may raise concerns about executive confidence in the company's future.
- Transaction Context: The sale was executed under a prearranged 10b5-1 trading plan designed to avoid the appearance of insider trading; however, this scheduling complicates the assessment of the insider's motivations, potentially affecting investor sentiment.
- Company Overview: Spyre Therapeutics is a preclinical-stage biopharmaceutical company focused on innovative antibody therapies, and despite a 36.3% stock increase over the past year, it remains a high-risk investment due to the lack of government-approved treatments.
- Market Performance: As of January 9, 2026, Spyre Therapeutics outperformed the Nasdaq Composite, which returned 24.3%, indicating that the market still holds an optimistic view on the company's potential growth prospects.
See More
Spyre Grants 42,000 Stock Options to Six Employees as Inducement Awards
- Stock Option Grant: On January 2, 2026, Spyre Therapeutics approved the grant of 42,000 stock options to six non-executive employees as equity inducement awards under the 2018 Equity Inducement Plan, highlighting the company's commitment to attracting talent.
- Exercise Price Setting: The stock options have an exercise price of $30.58 per share, equal to the closing price of Spyre's common stock on January 2, 2026, ensuring potential financial benefits for employees in the future.
- Vesting Mechanism: The stock options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, aimed at incentivizing employee retention through continuous service and enhancing team stability.
- Compliance Assurance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring the company's adherence to regulations and transparency in attracting and retaining key talent.
See More
Biotech Sector Sustains After-Hours Trading Gains
Market Activity: Several small- and mid-cap stocks experienced notable gains in after-hours trading, driven by investor sentiment and sector momentum rather than new company news.
Top Gainers: Spyre Therapeutics, Inc. (SYRE) led the gains with a 4.99% increase, followed by The Oncology Institute, Inc. (TOI) with a 5.49% rise, both without any fresh updates.
Sector Trends: Aurora Cannabis Inc. (ACB) and Lexeo Therapeutics, Inc. (LXEO) also saw gains, benefiting from renewed momentum in the cannabis and biotech sectors, respectively, despite no new announcements.
Significant Developments: Solid Biosciences Inc. (SLDB) recently highlighted a key milestone regarding Duchenne muscular dystrophy, which has positively influenced its stock performance, even without new news on the trading day.
See More
Spyre Therapeutics Grants 20,300 Stock Options to Employees as Inducement Awards
- Stock Option Grant: On December 1, 2025, Spyre Therapeutics approved the grant of 20,300 stock options to two non-executive employees with an exercise price of $28.66 per share, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the biotechnology sector.
- Incentive Plan: Under the 2018 Equity Inducement Plan, the granted options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, ensuring continuous service and thereby improving team stability and execution capabilities.
- Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring that the company adheres to relevant regulations while attracting talent, thus reducing compliance risks and enhancing investor confidence.
- Strategic Implications: By implementing such incentive measures, Spyre not only attracts top talent in the industry but also enhances its innovation capacity and market position in the highly competitive biopharmaceutical landscape.
See More
Spyre Grants 20,300 Stock Options to Employees Under Equity Inducement Plan
- Equity Incentive Plan: On December 1, 2025, Spyre Therapeutics approved the grant of 20,300 stock options to two non-executive employees, aimed at attracting and retaining talent through equity incentives, thereby enhancing the company's competitiveness in the biotechnology sector.
- Option Details: The options have an exercise price of $28.66 per share, in compliance with Nasdaq listing rules, and will vest one-fourth on the first anniversary of the employee's start date, with monthly vesting thereafter, ensuring long-term commitment from employees.
- Long-term Incentive Mechanism: By establishing a 10-year option term, Spyre aims to enhance employee motivation and loyalty through ongoing equity incentives, which will drive innovation in the fields of inflammatory bowel disease and rheumatic diseases.
- Strategic Implications: This equity incentive not only recognizes employee contributions but also reflects Spyre's confidence in future growth, which is expected to attract more high-quality talent and further advance the company's research pipeline.
See More
Spyre Therapeutics CEO Sells 15,000 Shares for $460K
- Insider Transaction: Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares on January 2 through open-market transactions for over $460,000, indicating management's approach to liquidity management in the company's stock.
- Holding Status: Post-transaction, Turtle retains approximately 671,907 shares valued at around $20.5 million, suggesting a strong confidence in the company's future prospects despite the sale.
- Transaction Context: The sale accounted for 2.2% of his direct holdings, with all shares sold being directly owned, reflecting transparency and compliance in insider trading practices.
- Market Performance: Over the past year, Spyre Therapeutics' stock has risen by 36.3%, outperforming the Nasdaq Composite's 24.3% return, indicating market recognition of its growth potential.
See More
Spyre Therapeutics CEO Cameron Turtle Sells 15,000 Shares for Over $460,000
- Insider Sale: Cameron Turtle, CEO of Spyre Therapeutics, sold 15,000 shares on January 2, 2026, for over $460,000, representing 2.2% of his holdings and reducing his direct ownership to 671,907 shares, which may raise concerns about executive confidence in the company's future.
- Transaction Context: The sale was executed under a prearranged 10b5-1 trading plan designed to avoid the appearance of insider trading; however, this scheduling complicates the assessment of the insider's motivations, potentially affecting investor sentiment.
- Company Overview: Spyre Therapeutics is a preclinical-stage biopharmaceutical company focused on innovative antibody therapies, and despite a 36.3% stock increase over the past year, it remains a high-risk investment due to the lack of government-approved treatments.
- Market Performance: As of January 9, 2026, Spyre Therapeutics outperformed the Nasdaq Composite, which returned 24.3%, indicating that the market still holds an optimistic view on the company's potential growth prospects.
See More
Spyre Grants 42,000 Stock Options to Six Employees as Inducement Awards
- Stock Option Grant: On January 2, 2026, Spyre Therapeutics approved the grant of 42,000 stock options to six non-executive employees as equity inducement awards under the 2018 Equity Inducement Plan, highlighting the company's commitment to attracting talent.
- Exercise Price Setting: The stock options have an exercise price of $30.58 per share, equal to the closing price of Spyre's common stock on January 2, 2026, ensuring potential financial benefits for employees in the future.
- Vesting Mechanism: The stock options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, aimed at incentivizing employee retention through continuous service and enhancing team stability.
- Compliance Assurance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring the company's adherence to regulations and transparency in attracting and retaining key talent.
See More
Biotech Sector Sustains After-Hours Trading Gains
Market Activity: Several small- and mid-cap stocks experienced notable gains in after-hours trading, driven by investor sentiment and sector momentum rather than new company news.
Top Gainers: Spyre Therapeutics, Inc. (SYRE) led the gains with a 4.99% increase, followed by The Oncology Institute, Inc. (TOI) with a 5.49% rise, both without any fresh updates.
Sector Trends: Aurora Cannabis Inc. (ACB) and Lexeo Therapeutics, Inc. (LXEO) also saw gains, benefiting from renewed momentum in the cannabis and biotech sectors, respectively, despite no new announcements.
Significant Developments: Solid Biosciences Inc. (SLDB) recently highlighted a key milestone regarding Duchenne muscular dystrophy, which has positively influenced its stock performance, even without new news on the trading day.
See More
Spyre Therapeutics Grants 20,300 Stock Options to Employees as Inducement Awards
- Stock Option Grant: On December 1, 2025, Spyre Therapeutics approved the grant of 20,300 stock options to two non-executive employees with an exercise price of $28.66 per share, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the biotechnology sector.
- Incentive Plan: Under the 2018 Equity Inducement Plan, the granted options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, ensuring continuous service and thereby improving team stability and execution capabilities.
- Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring that the company adheres to relevant regulations while attracting talent, thus reducing compliance risks and enhancing investor confidence.
- Strategic Implications: By implementing such incentive measures, Spyre not only attracts top talent in the industry but also enhances its innovation capacity and market position in the highly competitive biopharmaceutical landscape.
See More
Spyre Grants 20,300 Stock Options to Employees Under Equity Inducement Plan
- Equity Incentive Plan: On December 1, 2025, Spyre Therapeutics approved the grant of 20,300 stock options to two non-executive employees, aimed at attracting and retaining talent through equity incentives, thereby enhancing the company's competitiveness in the biotechnology sector.
- Option Details: The options have an exercise price of $28.66 per share, in compliance with Nasdaq listing rules, and will vest one-fourth on the first anniversary of the employee's start date, with monthly vesting thereafter, ensuring long-term commitment from employees.
- Long-term Incentive Mechanism: By establishing a 10-year option term, Spyre aims to enhance employee motivation and loyalty through ongoing equity incentives, which will drive innovation in the fields of inflammatory bowel disease and rheumatic diseases.
- Strategic Implications: This equity incentive not only recognizes employee contributions but also reflects Spyre's confidence in future growth, which is expected to attract more high-quality talent and further advance the company's research pipeline.
See More
